IRCT2017041533448N1
Completed
未知
Evaluation of comparative effect of intravitreal bevasizumab on visual acuity and central macular thickness in patient with central serous chorioretinopathy
Vice chancellor for research, Zahedan University of Medical Sciences0 sites30 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Central Serous Chorioretinoathy.
- Sponsor
- Vice chancellor for research, Zahedan University of Medical Sciences
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with visual loss (2 lines Snellen chart or more) and in scan (the thickness of the central part of the macula greater than 250 microns) diagnosis of central serous chorioretinopathy they laid is.
- •Exclusion criteria: Patient with visual loss with pathological retinal diseases other than Central serous retinopathy and diabetic retinopathy and hypertensive retinopathy and retinal dystrophies and patients who do not have the desire to enter the study.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Comparative study of the effect of intravitreal injection of bevacizumab versus simultaneous intravitreal injection of bevacizumab and triamcinolone acetonideRetinal vascular occlusions.Retinal vascular occlusionsIRCT20130812014333N185Kermanshah University of Medical Sciences58
Recruiting
Phase 3
The Comparison of Efficacy Between Iranian Made Ranibizumab and Imported Ranibizumab in Diabetic Patients with Macular EdemaIRCT20170303032845N1Aracell zist daru154
Active, not recruiting
Not Applicable
Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma - NDMacular oedemaMedDRA version: 6.1Level: HLGTClassification code 10047060EUCTR2006-002351-33-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
Active, not recruiting
Not Applicable
Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration - IVB JSAEUCTR2006-003170-99-ITIVERSITA DEGLI STUDI DI UDINE
Recruiting
Not Applicable
Clinical evaluation for the effects of intraocular tissue plasminogen activator administration in various eye diseasesVarious eye diseasesJPRN-UMIN000015726Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Japan50